NCT06096116: An ongoing trial by Octapharma
This trial is ongoing. It must report results 2 years, 12 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06096116 |
|---|---|
| Title | Phase 3, Double-blind, Placebo-controlled, Multicentre Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 21, 2024 |
| Completion date | March 31, 2028 |
| Required reporting date | March 31, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |